- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
This is a Virtual Event for PsychU members in Alaska; Arizona; Colorado; Idaho; Montana; Nevada; New Mexico; Oregon; El Paso, Texas; Utah, Washington, and Wyoming.
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.
Objectives:
- Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
- Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
- Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology
Featuring
Jessie Chambers, PhD (OPDC)
Medical Science Liaison
Simon Kim, PharmD (OPDC)
Medical & Scientific Liaison
Speakers Jessie Chambers, PhD and Simon Kim, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Related Events
-
Virtual Event – Care Coordination For Adult Patients With SMI – From Inpatient To Outpatient
May 22 12:00 pm to 1:00 pm -
Virtual Event – Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)
June 6 12:00 pm to 1:00 pm
Registration
Related Resources
-
2024 Mental Health America (MHA) Mental Health Month Toolkit
Downloadable Resource May 1, 2024In celebrating May Mental Health Month, MHA released their highly anticipated 2024 Mental Health Month toolkit! This year the toolkit theme is Where to Start: Mental Health in a Changing World. The…
-
Understanding Digital Therapeutics
Infographic April 22, 2024Digital therapeutics (DTx) deliver software-based interventions to patients to treat, manage, or prevent a disease or condition.
-
Understanding MDD Treatments With Neuroplastic Effects
Infographic April 22, 2024Researchers are exploring whether it is possible to leverage neuroplasticity to develop treatments for depression.
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: